

Table 1 Brief Summary of Findings

	Abstinence	Use	Lapse	Relapse	Retention	Harms
All Antidepressants: Bupropion, Desipramine, Fluoxetine, Mirtazapine, Nefazodone, Paroxetine, Sertraline, Venlafaxine	★★	★★	★	★	★★★	★★
Aminoketone: Bupropion	★	★	NA	NA	★★	∅
SSRIs: Fluoxetine, Paroxetine, and Sertraline	NA	NA	∅	∅	★★	★
SSRI in patients abstinent at Baseline: Sertraline	NA	NA	★	★	★	∅
All Antipsychotics: Aripiprazole, Haloperidol, Lamotrigine, Olanzapine, Quetiapine, Risperidone, Reserpine	★	★	∅	∅	★★	∅
Psychostimulants: Dexamphetamine, Lisdexamphetamine, Mazindol, Methamphetamine, Methylphenidate, Mixed Amphetamine Salts, Modafinil, Selegiline	★	★	NA	NA	★★	★★
Cognitive Enhancing Drugs: Memantine, Atomoxetine	∅	∅	NA	∅	∅	∅
Anxiolytic: Buspirone	∅	NA	∅	∅	∅	∅
Anticonvulsants/Muscle Relaxants: Baclofen, Carbamazepine, Gabapentin, Lamotrigine, Phenytoin, Tiagabine, Topiramate, Vigabatrin	NA	★★	NA	NA	★★	∅
Anticonvulsant: Topiramate	★	∅	NA	NA	★★	∅
Drugs for other substance use disorders: Acamprosate, Buprenorphine, Buprenorphine + Naloxone, Disulfiram, Naltrexone, Methadone, Varenicline	★	∅	∅	∅	∅	∅
Disulfiram	★	★	NA	NA	★★	★
Dopamine agonists: Amantadine, bromocriptine, L dopa/Carbidopa, pergolide, cabergoline, hydroxyergine, and pramipexole	★	NA	NA	NA	★★	NA

Shading represents the direction of effect:

(No color)	Unclear
Grey	No difference
Green	Evidence of benefit
Red	Favors placebo

Symbols represent the strength of the evidence:

NA	No evidence or not applicable
∅	Insufficient
★	Low
★★	Moderate
★★★	High